中国临床药理学杂志2016，Vol.32Issue(6)：511-513,3.DOI:10.13699/j.cnki.1001-6821.2016.06.010
伊马替尼、尼洛替尼和达沙替尼对慢性粒细胞白血病慢性期患者的临床疗效
Clinical effect of imatinib, nero imatinib and dasatinib on chronic myeloid leukemia in chronic phase
胡敏 1袁凯锋 1李晓明 1陈燕 1马涛 1邢宏运1
作者信息
- 1. 泸州医学院 附属医院 血液内科，四川 泸州646000
- 折叠
摘要
Abstract
Objective To compare the clinical efficacy and safety of ima-tinib, nilotinib and dasatinib on chronic myelogenous leukemia ( CML) in chronic phase patients and explore the best first -line treatment for chronic phase CML.Methods A total of 123 patients with chronic phase CML treated by tyrosine kinase inhibitors were divided into three groups:imatinib group A ( n=64 );nilotinib group B ( n=31 ) and da-satinib group C ( n =28 ).Based on the clinical data and follow -up records, the CCyR、CHR and MMR at 18 months were analyzed in three groups.Results MMR, CHR and CCyR showed a rising trend in ima-tinib group after 3, 6, 12, 18 months treatment.CCyR in group B and C had been significantly improved ( P<0.05 );CHR in group B and C had significant improvement ( P<0.01 ) compared with group A.There was no difference in CHR between three groups at any time.The safety results showed that there was no difference in three groups during the follow-up period.Conclusion Nilotinib and dasatinib treatment can obtain faster complete cytogenetic remission and major molecular remis-sion than imatinib, and the response to treatment is usually dramatic in these groups.关键词
慢性粒细胞白血病/酪氨酸激酶抑制剂/主要分子生物学缓解/完全细胞遗传学缓解Key words
chronic myeloid leukemia/tyrosine kinase inhibitor/molecular biology/complete cytogenetic remission分类
医药卫生引用本文复制引用
胡敏,袁凯锋,李晓明,陈燕,马涛,邢宏运..伊马替尼、尼洛替尼和达沙替尼对慢性粒细胞白血病慢性期患者的临床疗效[J].中国临床药理学杂志,2016,32(6):511-513,3.
